What happened
Shares of the clinical-stage biotech Inovio Pharmaceuticals(NASDAQ:INO) gained a respectable 10.9% over the course of May, according to data provided by S&P Global Market Intelligence. The DNA vaccine company’s shares rallied last month on the news that its pan-COVID-19 vaccine candidate, INO-4802, showed strong signs of efficacy across multiple strains of the virus in preclinical studies.
So what
Despite being one of the first American biotech companies to develop a COVID-19 vaccine…

Click here to view the original article.